PharmaCielo Ltd. (TSXV: PCLO) (OTC: PHCEF), the Canadian parent of Colombia’s cultivator and producer of medicinal-grade cannabis extracts PharmaCielo Colombia Holdings S.A.S., announced that it has completed the necessary permitting process required to enable Colombia’s first commercial export and sale of non-psychoactive (CBD) isolate.

The process fulfills the extensive and final regulatory obligations required, including individual approvals by the Colombian Ministries of Health and Justice, in order to commence product exportation.

Following the completion of the process, the company will now begin the process of confirming a series of international business relationships and configuring inaugural commercial shipments of high-grade medicinal CBD isolate, with a purity certificate of analysis (COA) of 99+% and meeting all other strict quality control standard requirements established by the Colombian government.

“Enabling product delivery to customers is one of the most exciting and memorable moments for any company, and we are thrilled about this accomplishment,” David Attard, the CEO of PharmaCielo, stated.

PharmaCielo is currently in advanced discussion with previously identified potential customers in multiple global markets, as part of which the export permitting process is a necessity, including logistical relations with its joint venture partners in Italy and Mexico.

Upon closure of the acquisition of Creso Pharma Ltd., expected later in the year, the number of potential international markets for PharmaCielo products export will significantly increase.

“We have already begun scaling up our Colombian operations and we are ready to deliver and prepared to support the expected growth in demand for our cannabinoid extracts, having achieved the Colombian industry’s first go-ahead to start exporting,” stated Andres Botero, chief operations officer of PharmaCielo Colombia Holdings S.A.S.